Search research articles
Contact Us
Filters
Showing results (51-60 of 115) with videos related to
Page
of 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2020
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
M E Salem, J Yin, R M Goldberg, et al.
ESMO Open
|
October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
D Rossini, A Boccaccino, A Sbrana, et al.
Cell Death and Differentiation
|
September 17, 2013
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis
S R Chan, C G Rickert, W Vermi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
R Obermannová, E Van Cutsem, T Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2023
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
J Taieb, F A Sinicrope, L Pederson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C Cremolini, F Loupakis, C Antoniotti, et al.
ESMO Open
|
February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C Antoniotti, M Carullo, D Rossini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open
|
August 20, 2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A Raimondi, G Fucà, A G Leone, et al.
ESMO Open
|
July 16, 2021
Intratumor morphologic and transcriptomic heterogeneity in <sup>V600E</sup>BRAF-mutated metastatic colorectal adenocarcinomas
V Angerilli, E Fontana, S Lonardi, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 115) with videos related to
Sort By:
Page
of 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2020
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
M E Salem, J Yin, R M Goldberg, et al.
ESMO Open
|
October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
D Rossini, A Boccaccino, A Sbrana, et al.
Cell Death and Differentiation
|
September 17, 2013
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis
S R Chan, C G Rickert, W Vermi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
R Obermannová, E Van Cutsem, T Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2023
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
J Taieb, F A Sinicrope, L Pederson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C Cremolini, F Loupakis, C Antoniotti, et al.
ESMO Open
|
February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C Antoniotti, M Carullo, D Rossini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open
|
August 20, 2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A Raimondi, G Fucà, A G Leone, et al.
ESMO Open
|
July 16, 2021
Intratumor morphologic and transcriptomic heterogeneity in <sup>V600E</sup>BRAF-mutated metastatic colorectal adenocarcinomas
V Angerilli, E Fontana, S Lonardi, et al.
Page
of 12